TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15024929

Group type: EXPERIMENTAL
Intervention: Observed single low-dose mefloquine (15 mg/kg) and artesunate (4 mg/kg)
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Observed single high-dose mefloquine (25 mg/kg) and artesunate (4 mg/kg)
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Observed artesunate 4 mg/kg on day 0 plus self-administered mefloquine 15 mg/kg on day 1 and 10 mg/kg on day 2 with artesunate 4 mg/kg/day on day 1 and 2
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: 3-day regimen under direct observation
Number of subjects: 736

Group type: COMPARATOR
Intervention: Single dose treatments
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: 3-day regimens
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: All 4 regimens
Number of subjects: 736
Study: 11585883

Group type: EXPERIMENTAL
Intervention: Distal-valved Bard Groshong catheter
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Proximal-valved Catheter Innovations Pressure Activated Safety Valve catheter
Number of subjects: 100
Study: 9679884

Group type: EXPERIMENTAL
Intervention: Melanotan‐II
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8005188

Group type: EXPERIMENTAL
Intervention: Intravenous terbutaline sulphate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous theophylline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous enprofylline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 12
Study: 2563096

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1007

Group type: COMPARATOR
Intervention: Aspirin 75 mg once daily
Number of subjects: 1007

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1007
Study: 31345135

Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment (IAT) with NCCT ASPECTS 7 to 10
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment (IAT) with NCCT ASPECTS 0 to 6
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment (IAT) with NCCT ASPECTS
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment (IAT) with diffusion weighted imaging ASPECTS
Number of subjects: 205
Study: 27808530

Group type: EXPERIMENTAL
Intervention: Direct cause statements (e.g., 'makes', 'increases')
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Can cause statements (e.g., 'can make', 'can increase')
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate cause statements (e.g., 'might cause', 'linked', 'associated with')
Number of subjects: 0
Study: 26081177

Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 26
Study: 24060195

Group type: EXPERIMENTAL
Intervention: Therapist-aided exposure therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 70
Study: 21130474

Group type: EXPERIMENTAL
Intervention: N‐MUF
Number of subjects: 50
Study: 19379609

Group type: EXPERIMENTAL
Intervention: CT-derived Lund-Mackay scores calculated by expert rhinologists
Number of subjects: 40

Group type: COMPARATOR
Intervention: Scores derived from accompanying radiology reports by blinded reviewers
Number of subjects: 40
Study: 17309946

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 1411
Study: 15024663

Group type: EXPERIMENTAL
Intervention: 20-s interval training (IT20; n=6)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 180-s interval training (IT180; n=7)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CON; n=7)
Number of subjects: 20
Study: 12195755

Group type: EXPERIMENTAL
Intervention: Continuation of pregnancy during breast cancer treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Potentially curative therapies administered during pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guidelines for managing breast cancer during pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregnancy after treatment for breast cancer
Number of subjects: 0
Study: 11477817

Group type: COMPARATOR
Intervention: Embolism chemotherapy (ECT)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Embolism chemotherapy (ECT) + immunotherapy
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Embolism chemotherapy (ECT) + Chinese herbal medicine
Number of subjects: 108
Study: 8017869

Group type: EXPERIMENTAL
Intervention: High dose interferon-beta 1b
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2688531

Group type: EXPERIMENTAL
Intervention: Iopromide 300
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ioxaglate 320 mgI/ml
Number of subjects: 24
Study: 4604977

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg/day
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 31188734

Group type: EXPERIMENTAL
Intervention: GnRH Agonist
Number of subjects: 80

Group type: COMPARATOR
Intervention: GnRH Antagonist
Number of subjects: 80
Study: 28336412

Group type: EXPERIMENTAL
Intervention: Video assisted laryngoscopy using the King Video Laryngoscope (KVL)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL)
Number of subjects: 82
Study: 26654517

Group type: EXPERIMENTAL
Intervention: General + INB anesthesia (Group B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: General + epidural anesthesia (Group C)
Number of subjects: 80

Group type: COMPARATOR
Intervention: General anesthesia (Group A)
Number of subjects: 80
Study: 23829055

Group type: EXPERIMENTAL
Intervention: Sertaconazole 2% cream
Number of subjects: 128

Group type: COMPARATOR
Intervention: Clotrimazole 1% cream
Number of subjects: 128
Study: 21668425

Group type: EXPERIMENTAL
Intervention: Narrowband ultraviolet B (NB‐UVB) phototherapy, 210 mJ cm(‐2) starting dose, increased by 10% each time, administered three times per week for 6 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group received time‐matched exposures to long‐wave UVA radiation.
Number of subjects: 0
Study: 18837418

Group type: EXPERIMENTAL
Intervention: Jumbo forceps
Number of subjects: 95

Group type: COMPARATOR
Intervention: Normal flexible forceps
Number of subjects: 95
Study: 16715642

Group type: EXPERIMENTAL
Intervention: Guided Reciprocal Peer Questioning (GRPQ) method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional senior seminar course
Number of subjects: 0
Study: 14530981

Group type: EXPERIMENTAL
Intervention: Mental imagination of a rowing race
Number of subjects: 56
Study: 11390337

Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA) therapy and subsequent immunoglobulin (IgG) substitution
Number of subjects: 25
Study: 9015001

Group type: EXPERIMENTAL
Intervention: DDD pacing for 3 months
Number of subjects: 21

Group type: COMPARATOR
Intervention: AAI pacing for 3 months
Number of subjects: 21
Study: 8304047

Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin (200 IU/day, two times)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 3461385

Group type: EXPERIMENTAL
Intervention: Single 600 mg dose of trimethoprim
Number of subjects: 60

Group type: COMPARATOR
Intervention: Five-day course of trimethoprim
Number of subjects: 60
Study: 30149889

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study: 27404012

Group type: EXPERIMENTAL
Intervention: Compensation of US $12.50 conditional on circumcision uptake (food vouchers)
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Lottery-based rewards with high-value prizes
Number of subjects: 903

Group type: COMPARATOR
Intervention: Control group (no compensation or lottery)
Number of subjects: 903
Study: 24092547

Group type: EXPERIMENTAL
Intervention: Transsphenoidal surgery (TS)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Somatostatin analogs (SAs)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Pegvisomant (PGV)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Overall treatment effect
Number of subjects: 37
Study: 22417905

Group type: EXPERIMENTAL
Intervention: EMLA cream (5%)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Lubricant gel
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 134
Study: 20733209

Group type: EXPERIMENTAL
Intervention: Crowd noise
Number of subjects: 0

Group type: COMPARATOR
Intervention: No crowd noise
Number of subjects: 0
Study: 18226326

Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin 10/20 mg combination tablet (EZE/SIMVA)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Doubling statin dose
Number of subjects: 367
Study: 16335010

Group type: EXPERIMENTAL
Intervention: Diaspirin cross‐linked hemoglobin (DCLHb)
Number of subjects: 28
Study: 14517196

Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg once daily for mild hepatic insufficiency patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg every-other-day for moderate hepatic insufficiency patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single intravenous doses of etoricoxib for both mild and moderate hepatic insufficiency patients
Number of subjects: 0
Study: 10877373

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 219

Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 219
Study: 9106321

Group type: EXPERIMENTAL
Intervention: Neuroreflexotherapy intervention
Number of subjects: 78

Group type: COMPARATOR
Intervention: Sham treatment (control)
Number of subjects: 78
Study: 8477136

Group type: EXPERIMENTAL
Intervention: PCA (Patient-Controlled Analgesia)
Number of subjects: 54

Group type: COMPARATOR
Intervention: PCA + CI (Patient-Controlled Analgesia plus Continuous Infusion)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: NCA (Nurse-Controlled Analgesia)
Number of subjects: 54
Study: 3942848

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29847157

Group type: EXPERIMENTAL
Intervention: Quetiapine (QUET)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 33
Study: 27544742

Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy (OMT) achieved group (548 patients, 18.2%)
Number of subjects: 3004

Group type: COMPARATOR
Intervention: Non-Optimal Medical Therapy (non-OMT) group (2,456 patients)
Number of subjects: 3004

Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy (OMT) achieved group
Number of subjects: 3004

Group type: COMPARATOR
Intervention: Non-Optimal Medical Therapy (non-OMT) group
Number of subjects: 3004
Study: 24362587

Group type: EXPERIMENTAL
Intervention: HBO and intranasal mometasone furoate (10 μl/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HBO and diclofenac sodium (10 mg/kg/day ip)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HBO group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not exposed to HBO)
Number of subjects: 40
Study: 22675945

Group type: EXPERIMENTAL
Intervention: Embryo glue
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Embryo glue (Control)
Number of subjects: 0
Study: 20926533

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study: 18592627

Group type: EXPERIMENTAL
Intervention: Hydrolysed formula
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Sucrose solution
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Herbal tea
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 175
Study: 15816571

Group type: EXPERIMENTAL
Intervention: Early ambulation (Group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Recumbent position (Group 2)
Number of subjects: 60
Study: 12553444

Group type: EXPERIMENTAL
Intervention: Transthyretin and albumin markers
Number of subjects: 0
Study: 9428876

Group type: EXPERIMENTAL
Intervention: sufentanil/propofol (Group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: alfentanil/propofol (Group 2)
Number of subjects: 40
Study: 7697841

Group type: EXPERIMENTAL
Intervention: Hirulog 0.5 mg/kg per hour for 12 hours followed by 0.1 mg/kg per hour
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Hirulog 1.0 mg/kg per hour for 12 hours followed by placebo
Number of subjects: 68

Group type: COMPARATOR
Intervention: Heparin 5000 U bolus followed by 1000 U/h titrated to an aPTT 2 to 2.5 times control after 12 hours
Number of subjects: 68
Study: 3261140

Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Etomidate
Number of subjects: 80
Study: 30510523

Group type: EXPERIMENTAL
Intervention: Metacognitive Therapy (MCT)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Behavioral Activation (BA)
Number of subjects: 128
Study: 28842953

Group type: EXPERIMENTAL
Intervention: Novel body shape descriptors based on 3D body images
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Predictive models for VAT and SAT
Number of subjects: 121
Study: 25778833

Group type: EXPERIMENTAL
Intervention: Exercise (30 min of moderate-intensity walking)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Resting (no exercise)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 28

Group type: COMPARATOR
Intervention: Resting
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: EIdiff (difference in EI between exercise and resting)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Classification of 'compensators'/'non-compensators'
Number of subjects: 28
Study: 23865624

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention consisting of two individually delivered counseling sessions focusing on diet, physical activity, and weight monitoring.
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention.
Number of subjects: 250
Study: 21663949

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg plus Ezetimibe 10 mg daily
Number of subjects: 9270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9270
Study: 19216002

Group type: EXPERIMENTAL
Intervention: Wearing surgical face masks
Number of subjects: 32

Group type: COMPARATOR
Intervention: No face masks (control group)
Number of subjects: 32
Study: 16914464

Group type: EXPERIMENTAL
Intervention: Etomidate-Lipuro
Number of subjects: 80

Group type: COMPARATOR
Intervention: Propofol with added lidocaine
Number of subjects: 80
Study: 15598773

Group type: EXPERIMENTAL
Intervention: 0.16% all-trans retinoic acid (atRA) for 4 days
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: 0.28% all-trans retinoic acid (atRA) for 4 days
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: 0.36% all-trans retinoic acid (atRA) for 4 days
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: CIN II at baseline
Number of subjects: 175
Study: 11719733

Group type: EXPERIMENTAL
Intervention: Cyclosporine with red wine (12 oz of Blackstone Merlot, 1996)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cyclosporine with water (control)
Number of subjects: 12
Study: 9140320

Group type: EXPERIMENTAL
Intervention: Activated charcoal (25 g) given immediately after verapamil 80 mg (conventional formulation)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Activated charcoal (25 g) given 2 hours after verapamil 80 mg (conventional formulation)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Activated charcoal (25 g) given immediately after verapamil 240 mg (slow-release formulation)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Activated charcoal (25 g) given 2 hours after verapamil 240 mg (slow-release formulation)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Activated charcoal (25 g) given 4 hours after verapamil 240 mg (slow-release formulation)
Number of subjects: 17
Study: 7951964

Group type: EXPERIMENTAL
Intervention: Pronation orthosis
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Supination orthosis
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (no orthosis)
Number of subjects: 23
Study: 3904433

Group type: EXPERIMENTAL
Intervention: isoxicam (200 to 400 mg per day, then reduced to 200 mg per day)
Number of subjects: 745

Group type: COMPARATOR
Intervention: isoxicam (open-label after double-blind phase)
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: isoxicam
Number of subjects: 745
Study: 27924679

Group type: EXPERIMENTAL
Intervention: 2000 IU vitamin D supplementation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 26744983

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 296

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study: 23861093

Group type: EXPERIMENTAL
Intervention: Parent alliance with therapist in Family-Based Treatment (FBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined parent alliance in FBT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Difference in alliance scores between mothers and fathers, and parents and their child
Number of subjects: 0
Study: 22480146

Group type: EXPERIMENTAL
Intervention: Adjuvant insulin therapy
Number of subjects: 280

Group type: COMPARATOR
Intervention: Dietary regime
Number of subjects: 280
Study: 20450373

Group type: EXPERIMENTAL
Intervention: Triclosan-containing dentifrice (CT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 39
Study: 18024525

Group type: EXPERIMENTAL
Intervention: Baseline HSP27 plasma concentration
Number of subjects: 510

Group type: COMPARATOR
Intervention: Control group (women matched for age and smoking, free of cardiovascular disease)
Number of subjects: 510
Study: 17313718

Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) 3 x 4 g/d for 6 months
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 15496045

Group type: EXPERIMENTAL
Intervention: ICaps AREDS Formula (Alcon)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ocuvite PreserVision (Bausch & Lomb)
Number of subjects: 50
Study: 11533794

Group type: COMPARATOR
Intervention: Chloroquine (25mg/kg wt)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketotifen (0.13 mg/kg body wt) with Chloroquine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketotifen with Fansidar (33.3mg/kg body wt)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketotifen with both Chloroquine and Fansidar
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chloroquine with Ketotifen
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketotifen plus Fansidar
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of Chloroquine, Ketotifen, and Fansidar
Number of subjects: 60
Study: 9107182

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg BID)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Enalapril plus aspirin (325 mg/d)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hydralazine-isosorbide dinitrate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 1526054

Group type: EXPERIMENTAL
Intervention: Blocks of the infraorbital, infratrochlear and external nasal nerves by intranasal infiltration
Number of subjects: 50

Group type: COMPARATOR
Intervention: Generalized infiltration of the nasal dorsum by an external route
Number of subjects: 50
Study: 2861067

Group type: COMPARATOR
Intervention: 1 mg nebulized fenoterol (group A)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 1 mg fenoterol and 0.5 mg ipratropium (group B)
Number of subjects: 28
Study: 31838440

Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR) program
Number of subjects: 43

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 43
Study: 30913162

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CM) 0.3 g·kg⋅d for 1 week (loading phase) and 5 g·d for 7 weeks (maintenance phase)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CM)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 19
Study: 26385030

Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 221

Group type: COMPARATOR
Intervention: Intravenous loop diuretics
Number of subjects: 221
Study: 23730862

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention for 12 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 58
Study: 21957718

Group type: EXPERIMENTAL
Intervention: Teacher training programs in physical education instruction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical education instruction
Number of subjects: 0
Study: 19048243

Group type: COMPARATOR
Intervention: Exogenous alkaline phosphatase (AP) administered via 10-min IV infusions or 24-72 h continuous IV infusion (132.5-200 U kg(‐1) 24 h(‐1))
Number of subjects: 103

Group type: COMPARATOR
Intervention: Exogenous alkaline phosphatase (AP) administered via 10-min IV infusions
Number of subjects: 103

Group type: COMPARATOR
Intervention: Exogenous alkaline phosphatase (AP) administered via 24-72 h continuous IV infusion
Number of subjects: 103

Group type: COMPARATOR
Intervention: Exogenous alkaline phosphatase (AP)
Number of subjects: 103
Study: 16870769

Group type: EXPERIMENTAL
Intervention: FPV plus LPV/RTV at 700 mg plus 400 mg/100 mg q12h simultaneously
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: FPV/RTV at 700 mg/100 mg q12h plus LPV/RTV at 400 mg/100 mg q12h, with doses separated by 4 h
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: FPV/RTV at 700 mg/100 mg q12h plus LPV/RTV at 400 mg/100 mg q12h, with doses separated by 12 h
Number of subjects: 11
Study: 12779035

Group type: EXPERIMENTAL
Intervention: Mixtard 50 HM
Number of subjects: 26

Group type: COMPARATOR
Intervention: Mixtard 30 HM
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: NovoPen 3
Number of subjects: 26

Group type: COMPARATOR
Intervention: Traditional syringe
Number of subjects: 26
Study: 10948445

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative chemotherapy
Number of subjects: 0
Study: 9376337

Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30